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Spatial and temporal epithelial ovarian
cancer cell heterogeneity impacts Maraba
virus oncolytic potential
Jessica G. Tong1,3, Yudith Ramos Valdes1, Milani Sivapragasam1,3, John W. Barrett2, John C. Bell7,8, David Stojdl9,
Gabriel E. DiMattia1,4,5 and Trevor G. Shepherd1,3,5,6,10*
Abstract
Background: Epithelial ovarian cancer exhibits extensive interpatient and intratumoral heterogeneity, which can
hinder successful treatment strategies. Herein, we investigated the efficacy of an emerging oncolytic, Maraba virus
(MRBV), in an in vitro model of ovarian tumour heterogeneity.
Methods: Four ovarian high-grade serous cancer (HGSC) cell lines were isolated and established from a single patient
at four points during disease progression. Limiting-dilution subcloning generated seven additional subclone lines to
assess intratumoral heterogeneity. MRBV entry and oncolytic efficacy were assessed among all 11 cell lines. Low-density
receptor (LDLR) expression, conditioned media treatments and co-cultures were performed to determine factors
impacting MRBV oncolysis.
Results: Temporal and intratumoral heterogeneity identified two subpopulations of cells: one that was highly sensitive
to MRBV, and another set which exhibited 1000-fold reduced susceptibility to MRBV-mediated oncolysis. We explored
both intracellular and extracellular mechanisms influencing sensitivity to MRBV and identified that LDLR can partially
mediate MRBV infection. LDLR expression, however, was not the singular determinant of sensitivity to MRBV among
the HGSC cell lines and subclones. We verified that there were no apparent extracellular factors, such as type I interferon
responses, contributing to MRBV resistance. However, direct cell-cell contact by co-culture of MRBV-resistant subclones
with sensitive cells restored virus infection and oncolytic killing of mixed population.
Conclusions: Our data is the first to demonstrate differential efficacy of an oncolytic virus in the context of both spatial
and temporal heterogeneity of HGSC cells and to evaluate whether it will constitute a barrier to effective viral oncolytic
therapy.
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Background
Late-stage diagnosis of epithelial ovarian cancer (EOC)
and acquisition of chemotherapeutic resistance in recur-
rent disease are the major contributors to poor patient
prognosis [1, 2]. Debulking surgery either before or after
adjuvant chemotherapy is the standard treatment for
ovarian cancer patients with metastatic disease. Under
this treatment regimen, EOC is still the most lethal
gynaecologic malignancy in the developed world with a
5-year survival rate of less than a 30% [3]. Following
chemotherapy, the selection and expansion of platinum-
resistant EOC cells results in the recurrence of aggres-
sive disease that is largely incurable with second-line
treatment options. Chemoresistance, particularly in
high-grade serous cancer (HGSC) of the ovary, the most
common histotype of EOC, is fueled by profound gen-
omic instability caused by DNA repair pathway deficien-
cies and universal loss of TP53 which results in a high
degree of intratumoral cellular heterogeneity [4–6]. As
observed in many cancers, intratumoral heterogeneity
generates a high degree of phenotypic variability which
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can manifest as differential responses to therapies.
Thus, there is significant demand for more effective
therapeutics that target disease heterogeneity more
effectively, thereby increasing progression-free survival
for these patients.
Cancer cells naturally gain survival- and growth-
enhancing properties through the selection and ex-
pansion of specific clones within a tumour. In doing
so, aggressive cancer cells may also lose many intra-
cellular pathogen defense mechanisms while inducing
immunosuppressive mechanisms. Oncolytic virother-
apy exploits these defects in intracellular defense to
selectively replicate in malignant cells [7]. Additional
changes in the tumour microenvironment, such as
decreased immune surveillance, also enhance virus
targeting of cancers. For example, mutations in inter-
feron (IFN) and in other proteins in this signaling
pathway are frequently seen in cancer cells as they
are major drivers of anti-tumour immunity [8]. How-
ever, type I IFNs are also key antiviral signaling molecules
found in all somatic cells thereby making cancer cells se-
lectively infected and killed by oncolytic viruses [9].
Many rhadbdoviruses, including Maraba virus (MRBV),
represent promising oncolytic viral vectors because of
their susceptibility to IFN signaling as well as innate
and adaptive immune responses making these viruses
relatively non-pathogenic in healthy humans. Thus,
tumours that are deficient in immunosurveillance path-
ways have increased susceptibility to these viruses.
Currently, a construct of MRBV armed with a tumour-
associated antigen, MAGE A3 is being evaluated in a
phase I/II clinical trial in conjunction with adenovirus-
MAGE A3 to investigate their immunostimulatory
activity and oncolytic potential (clinicaltrials.gov iden-
tifier: NCT02285816).
In a previous cross-comparison of three oncolytic
viruses, we observed potent oncolytic effects of MRBV
in several EOC cell lines [10]. Infections of EOC cell
lines cultured as adherent cells and three-dimensional
spheroids in suspension revealed that MRBV was the
most potent at inducing oncolysis. Furthermore, we
identified the low-density lipoprotein receptor (LDLR)
and its family members as partial mediators of MRBV
entry that may be used to predetermine MRBV oncoly-
sis of cancer cells. However, the potential for resistance
to MRBV treatment has yet to be determined in a het-
erogeneous EOC model. Herein, our objective was to
examine the efficacy of MRBV infection and oncolytic
killing in the context of temporal and spatial hetero-
geneity of malignant EOC cells from a patient with
recurrent disease. Direct analysis of multiple isolates
from this patient with metastatic HGSC of the ovary
may provide evidence for intratumoral heterogeneity
impacting MRBV oncolytic efficacy. Moreover, it is
unclear whether temporal changes in a tumour cell po-
pulation, particularly after chemotherapy, may cause mo-
lecular and cellular changes that affect MRBV infection
and oncolysis. Thus, we hypothesized that the high degree
of tumour cell heterogeneity in ovarian HGSC would yield
differential MRBV oncolytic efficacy and potential resist-
ance mechanisms.
Methods
Cell culture
The patient in this study initially presented with stage
IIIC disease and was managed by surgical debulking
followed by six cycles of carboplatin and paclitaxel
combination chemotherapy. Histopathological assess-
ment concluded that this patient’s malignancy displayed
a mixed tumour morphology consisting of 70% serous
and 30% clear cell adenocarcinoma. Upon disease re-
currence, ascites fluid was collected on four different
occasions (Fig. 1a) by paracentesis to initiate primary
cell cultures as described previously [11]. To establish
early-passage cell lines iOvCa105, iOvCa131, iOvCa142,
and iOvCa147, malignant cells were propagated after
removal of non-cancer cells by differential trypsi-
nization from the mixed ascites-derived cultures. The
iOvCa147 line was used in limiting-dilution subcultur-
ing with each well of two 96-well cluster dishes seeded
at 0.3 cells per well. Subclones were expanded from
single cells to generate all seven lines used in this study:
iOvCa147-B3, −C8, −E2, −F5, −F8, −G4, and -G7. All
cell lines and subclones were subjected to short-tandem
repeat (STR) analysis, which verified that they
originated from the single source. All cell lines were
cultured continuously in Dulbecco’s Modified Eagle
medium/Ham’s F12 (Wisent) supplemented with 10%
FBS (Wisent). Cells were grown in a 37 °C humidified
atmosphere of 95% air and 5% CO2. Adherent cells
were maintained on tissue culture-treated polystyrene
(Sarstedt, Newton, NC). Spheroids were maintained on
Ultra-Low Attachment (ULA®) cultureware (Corning,
Corning, NY), which is coated with a hydrophilic, neu-
trally charged hydrogel to prevent cell attachment. All
patient-derived cells were used in accordance with The
University of Western Ontario Human Research Ethics
Board approved protocol (UWO HSREB 12668E).
Virus production
Vero cells were infected with MRBV at multiplicity-of-
infection (MOI) 0.01 [9]. Twenty hours after infection,
supernatant was collected and virus was purified using a
0.2-μm filter [10]. MRBV MG1 mutant strain expressing
GFP used in these experiments has been described pre-
viously [9].
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Virus infection of EOC cells
Primary EOC cells were seeded at 10,000 cells per well of
a 96-well plate and were infected the following day at
MOI 0.001, 0.01, 0.1, 1, and 10. The appropriate UV-
inactivated virus at MOI 10 or no virus (mock-infected)
were used as controls. Seventy-two hours after infection,
viability was assayed using CellTiter-Glo® Luminescent
Cell Viability Assay (Promega, Madison, WI). For infec-
tion of EOC spheroids, cells were seeded at 50,000 cells
per well of a 24-well ULA cluster plate (Corning, Corning,
NY) and spheroids were allowed to form over 72 h. Sphe-
roids were then infected at MOI 0.01, 0.1, 1, and 10 using
the same controls as described for adherent cell infections.
Phase contrast and fluorescent images of infected cells
and spheroids were captured during each experiment
using a Leica DMI 4000B inverted microscope.
Virus entry quantitation
iOvCa147-F8 and iOvCa147-G4 cells were infected with
MRBV at an MOI of 0.1 at 4 °C to allow synchronous
virus adsorption to the cells. After 1 h, supernatant con-
taining uninfected virus was removed and titrated on
Vero cells. Agarose overlay and plaque assay was per-
formed to determine virus concentration through limit-
ing dilutions. Virus infection containing no cells was
performed as a negative control to normalize total
MRBV concentration collected at 0% infection.
a
b
Fig. 1 Temporal tumour cell biology impacts MRBV oncolytic efficacy in vitro. a. Serum CA-125 concentration (units per mL) for the patient from
whom ascites samples were collected to derive new cell lines from October 2008 to March 2012 comprising the complete clinical course of her
disease. iOvCA105, iOvCa131, iOvCa142, and iOvCa147 samples were derived from multiple ascites isolated upon first relapse and over a 14-month
period (upward arrows). iOvCa105 cells were isolated October 2010 after first relapse with platinum-sensitive disease. iOvCa131, iOvCa142, and
iOvCa147 were collected in close succession one year later between October 2011 and December 2011 upon second recurrence and acquisition of
platinum resistance. b. Cells from all four cell lines were seeded at 10,000 cells per well of a 96-well plate and infected with different doses of MRBV as
indicated, or UV-inactivated MRBV as a control. Cells were assayed for viability using CellTiter-Glo® reagent at 72 h post-infection. (*, p < 0.05; **, p < 0.01;
***, p < 0.001; ****, p < 0.0001, as determined by one-way ANOVA and Dunnett’s posthoc test)
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LDLR knockdown
iOvCa147-F8 and iOvCa147-E2 cells were seeded at
20,000 cells per well of 48-well plates and transfected
16 h after seeding with siLDLR SMARTPool RNA or
with siNT (non-targeting control siRNA) using Dharma-
FECT1 transfection reagent (Dharmacon). At 48 h post-
transfection, cells were used for infection experiments.
The LDLR-related family member inhibitor, receptor-
associated protein (RAP), was used at a concentration of
100 nM for 1 h [12] DMSO served as a vehicle control.
After incubation, MRBV was added and virus entry and
viability were assessed as described above.
Media swapping experiments
Media swap pre-infection
Cells were seeded at 10,000 cells per well of a 96-well
plate. Sixteen hours post seeding, conditioned media
from both iOvCa147-F8 and iOvCa147-G4 was either
replaced with fresh media, swapped between the two
clones, or left unchanged. Cells were then infected at an
MOI of 0.1 for 1 h and viability was assessed 48 h after
infection by CellTiter-Glo®.
Media swap post-infection
Cells were seeded at 10,000 cells per well of a 96-well
plate. Sixteen hours post-seeding, cells were infected
with MRBV at MOI 0.1 for 1 h followed by media
change. At 12 h, fresh media was either replaced, condi-
tioned media was swapped between iOvCa147-F8 and
iOvCa147-G4 subclone cells, or were left unchanged.
CellTiter-Glo® assays were performed for cell viability
48 h after infection.
Quantitative RT-PCR
iOvCa147-F8, iOvCa147-G4, and iOvCa147-B3 clones
were seeded at 500,000 cells per well of a 6-well plate.
Sixteen hours post-seeding, cells were infected with
MRBV at an MOI of 1 or UV-inactivated MRBV at an
MOI of 1 for 6 h. The A549 lung carcinoma cell line
was used as a positive control for an intact type I IFN
response [13]. Total RNA was isolated from both non-
infected and infected cells using Qiagen RNeasy Mini
Kit (Qiagen, Valencia, CA). Purified RNA was quantified
using an ND-1000 spectrophotometer (NanoDrop tech-
nologies, Wilmington, DE). Reverse transcription was
performed using total RNA isolated and Superscript II
reverse transcriptase (Invitrogen) as per manufacturer’s
instructions. PCR reactions were carried out using
Brilliant SYBR Green QPCR Master Mix (Agilent Tech-
nologies/Stratagene) and a Stratagene Mx3000P machine
with data exported to Microsoft Excel for analysis.
IFNβ1 and GAPDH primers were used as previously
described [13]. GAPDH served as an internal control for
RNA input and quantification was performed using the
ΔΔCt method [14].
Co-culture experiments
Co-cultures of iOvCa147-F8 and iOvCa147-G4 cells
were seeded in 24-well plates at a total of 100,000 cells
per well. Wells containing only 100% iOvCa147-F8 or
iOvCa147-G4 cells were used as normalization controls
for MRBV effect on viability (sensitive and resistant,
respectively). An increasing proportion of iOvCa147-F8
cells were titrated into the iOvCa147-G4 co-culture
(G4:F8 ratio: 98:2, 90:2, 75:25, 50:50, and 25:75) with
total number of cells consistent at 100,000 cells per well.
Sixteen hours post-seeding, cells were infected with
MRBV at an MOI of 0.05 and viability was measured
48 h post-infection using CellTiter-Glo®.
Cell tracker dye co-culture images
Confluent 10-cm plates of iOvCa147-F8 cells were
stained with Molecular Probes™ Lipophilic Tracer DiI at
1:500 dilutions (ThermoFisher Scientific, Waltham,
MA). Confluent 10-cm plates of iOvCa147-G4 cells were
stained with CellTracker™ Blue CMAC Dye at a 1:500
dilution (ThermoFisher Scientific, Waltham, MA). Cells
were stained for 1 h and subsequently seeded and
infected as described above. Fluorescent images (GFP,
DiI, and CMAC) were captured at 24 h post-infection
using a Leica DMI 4000B inverted microscope.
Immunoblotting
Cell lysates were generated using a modified radioimmu-
noprecipitation assay (RIPA) buffer [50 mM HEPES
pH 7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2,
1 nM ethylene glycol tetraacetic acid, 1 nM sodium
orthovanadate, 10 mM sodium pyrophosphate, 10 mM
sodium fluoride, 1% Triton-X-100, 1% sodium deoxycho-
late, 0.1% sodium dodecyl sulfate, 1 mM phenylmethyl-
sulfonyl fluoride, 1× protease inhibitor cocktail (Roche,
Laval, QC)] as described previously [10]. Lysates were
incubated on ice for 20 min and vortexed to ensure
complete lysis prior to centrifugation. Protein concentra-
tions were determined by Bradford assay using Protein
Assay Dye Reagent (BioRad, Mississauga, ON). Thirty
micrograms of lysates were electrophoresed on an 8%
sodium dodecyl sulphate-polyacrylamide electrophoresis
gel and transferred to a polyvinylidene difluoride mem-
brane (Roche, Mississauga, ON). Blots were blocked
with 5% skim milk in Tris-buffered saline with Tween 20
(TBST; 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1%
Tween 20) for 1 h, then blots were incubated overnight
on a rocking platform at 4 °C with specific antibodies at
1:1000 dilution in BSA/ TBST [anti-LDLR (Abcam,
ab14056; Cambridge, MA); anti-actin (Sigma)]. Blots were
washed using TBST and incubated with peroxidase-
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conjugated anti-rabbit IgG (GE Healthcare) for 1 h at
1:10,000 dilution in 5% skim milk/TBST for the α-LDLR
antibody, or 5% BSA/TBST for α-actin at room
temperature. Blots were washed again using TBST
followed by incubation with Luminata Forte Western
horseradish peroxidase substrate (Millipore, Etobicoke,
ON) and visualized with the ChemiDoc MP System
(BioRad, Mississauga, ON).
Statistical analysis
Statistical significance was determined using GraphPad
Prism 6 (GraphPad Software, San Diego, CA) by
unpaired two-tailed Student’s t-test or one-way analysis
of variance followed by a Tukey’s posthoc test, or
Dunnett’s posthoc test when comparing to a single con-
trol sample. Levels of statistical significance indicated
in each figure are as follows: *, p < 0.05; **, p < 0.01; ***,
p < 0.001; ****, p < 0.0001.
Results
HGSC tumour cell heterogeneity impacts MRBV oncolytic
efficacy
We commonly isolate cancer cells from the ascites of
patients with metastatic EOC to perform in vitro cell
culture experimentation [15]. From one EOC patient
with a mixed HGSC and clear cell carcinoma (70%
HGSC, 30% clear cell) and previously treated with
debulking surgery and carboplatin/paclitaxel chemo-
therapy, we received four independent isolates over
14 months after disease recurrence (Fig. 1a). The resul-
tant cell lines were confirmed to be HGSC with the
universal presence of a TP53 R280K missense mutation.
Using these four lines we sought to investigate the
effects of temporal changes on EOC cell susceptibility to
MRBV oncolytic infection and cell killing. We observed
that iOvCa105 and iOvCa147 cell lines, which were the
first and last isolates received, were highly sensitive to
MRBV with complete oncolysis achieved by MOI 0.01
after 3 d post-infection. This result was in stark con-
trast to iOvCa131 and iOvCa142 cell lines isolated from
the same patient where only partial oncolysis was ob-
served, even at MRBV concentrations as high as an
MOI of 1 after 3 d of infection; complete oncolysis in
these two lines was not achieved for any virus concen-
tration tested (Fig. 1b). These results indicated that the
metastatic HGSC cell population in this patient was
dynamic over time and could be heterogeneous with re-
spect to MRBV sensitivity.
We next sought to explore this inherent intra-patient
HGSC heterogeneity by using several subcloned lines
expanded from single cells of the MRBV-sensitive
iOvCa147 cell line. Using a set of seven different subclo-
nal lines, MRBV infections were performed and viability
was measured 3 d post-infection. We observed two
distinct responses to MRBV infection among the clones:
one group of four subclones demonstrated complete
oncolysis at less than or equal to an MOI of 0.1, and
another group of three subclones exhibited 1000-fold
reduced sensitivity to MRBV (Fig. 2a). In fact, complete
oncolysis was not achieved in these ‘resistant’ subclones
even at an MOI of 10. Indeed, we observed only modest
cytopathic effect (CPE) in small patches of GFP-positive
iOvCa147-G4 resistant cellsafter 72 h of MRBV in-
fection, whereas there was widespread CPE signifying
productive MRBV replication in iOvCa147-F8 sensitive
cells (Fig. 2b). Taken together, these results represent the
first direct example of how both temporal and spatial
heterogeneity in metastatic HGSC of the ovary can im-
pact MRBV oncolytic efficacy.
Low-density lipoprotein receptor (LDLR) is required for
efficient MRBV entry
As a first step to determine factors affecting differential
MRBV oncolysis in HGSC cell subpopulations, we evalu-
ated whether cell-associated MRBV was altered between
sensitive and resistant subclone cell lines. We infected
iOvCa147-F8 (sensitive) and iOvCa147-G4 (resistant)
cell lines with MRBV for one hour after which we quan-
tified the remaining virus in the media. Nearly 25% of
MRBV entered iOvCa147-F8 cells, yet only 5% of MRBV
entered iOvCa147-G4 cells (Fig. 3a).
We have previously established a link between the ex-
pression of LDLR and MRBV entry [10], therefore we
determined whether differences in LDLR expression be-
tween the iOvCa147-F8 and iOvCa147-G4 subclones
affects their susceptibility to MRBV infection. Analysis
of gene copy-number alterations in serous ovarian
adenocarcinoma using The Cancer Genome Atlas data
[16, 17] revealed that over 10% of tumours show LDLR
gene amplification with an additional 8/590 samples
showing elevated mRNA expression (Additional file 1:
Figure S1). Therefore, we determined whether LDLR
protein was differentially expressed between sensitive
and resistant clonal lines. We examined LDLR expres-
sion in iOvCa147-F8 and iOvCa147-G4 cells with and
without MRBV infection. Indeed, iOvCa147-F8 cells
expressed higher levels of LDLR as compared with
iOvCa147-G4 cells (Fig. 3b). In response to both UV-
inactivated MRBV (binds and enters cells, but does not
replicate) and replication-competent MRBV, LDLR ex-
pression was slightly decreased in iOvCa147-F8 cells.
This may indicate virus-binding to the LDLR, followed
by endocytosis and lysosomal degradation of the inter-
nalized receptor [18]. This result was distinct from
iOvCa147-G4 cells as the lower LDLR expression in this
resistant subclone cell line did not change in response to
virus (Fig. 3b), thus explaining deficiency in MRBV bind-
ing and entry.
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We previously reported reduced LDLR expression in
EOC cell lines during spheroid formation which corre-
lated with decreased MRBV entry into spheroid cells,
and this was confirmed by siRNA-mediated knockdown
of LDLR expression in adherent cells [10]. Indeed, we
observed a decrease in endogenous LDLR expression in
iOvCa147-F8 spheroids, which correlated with statisti-
cally significant increase in cell viability after MRBV in-
fection to levels equalling the resistant iOvCa147-G4
subclone (Additional file 2: Figure S2). With this correla-
tive data linking LDLR expression with virus infectivity
in iOvCa147-F8 and -G4 cells, we sought to determine if
decreased LDLR would impact susceptibility of sensitive
HGSC cells to virus infection. As expected, LDLR
knockdown using SMARTpool siRNA in two different
MRBV-sensitive subclone cell lines, iOvCa147-F8 and
-E2 (Fig. 3c), significantly decreased MRBV entry
(Fig. 3d) and oncolytic potential (Fig. 3E, and Additional
file 3: Figure S3). Validation of LDLR silencing and
ablation of MRBV oncolytic potential was performed
using two individual siRNAs from the SMARTpool
(Additional file 3: Figure S3a,b). The inhibitor of LDL-
related receptors, RAP, reduced MRBV entry in
iOvCa147-E2 clones, but not iOvCa147-F8 cells
(Fig. 3d) and RAP had no effect on resultant MRBV
oncolytic potential in either of these two sensitive
HGSC subclone cell lines (Fig. 3e). These data indicate
that LDLR is an important mediator controlling virus
entry rather than its receptor family members similar
to what we had documented previously [10].
Given that EOC cells require sufficient LDLR expres-
sion to mediate efficient MRBV entry [10], we sought
to determine whether endogenous LDLR protein ex-
pression on its own was sufficient to predict HGSC cell
Fig. 2 Intratumoral heterogeneity impacts MRBV oncolytic efficacy in vitro. a. Seven subcloned derivatives from iOvCa147 were generated through
limiting dilution culturing and single-cell expansion to create homogeneous cell lines from the original heterogeneous cell line population. Resultant
cells were seeded at 10,000 cells per well of a 96-well plate and infected 24 h post-seeding. Cells were assayed for viability using CellTiter-Glo at 72 h
post-infection. (**, p < 0.01; ****, p < 0.0001, as determined by one-way ANOVA and Dunnett’s posthoc test). b. Images of MRBV-infected cells were
captured at 72 h post-infection using bright-field and fluorescence microscopy at 50× original magnification
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susceptibility to MRBV oncolysis. We assessed LDLR
expression in the four independent isolates, iOvCa105,
iOvCa131, iOvCa142, and iOvCa147, and all seven
subclone cell lines generated from iOvCa147. We did
not observe, however, a direct correlation between sen-
sitivity and resistance to MRBV infection with overall
LDLR expression among all cell lines (Additional file 4:
Figure S4). This suggests that although LDLR regulates
MRBV entry into HGSC cells, its expression alone does
not predict sensitivity to MRBV oncolytic infection.
Secreted factors do not impart MRBV sensitivity or
resistance
We next sought to determine whether MRBV-resistance
in HGSC subclones is mediated by secreted factors that
could reduce infection of sensitive cells. Since MRBV in-
fection can elicit a robust anti-viral type I IFN response
in normal cells [19], we first tested whether MRBV-
infected HGSC cells generated this classic response.
Quantitative RT-PCR analysis of IFNB1 mRNA expres-
sion in sensitive iOvCa147-F8 cells, and two resistant
a b
c
d e
Fig. 3 Differences in LDLR expression can impact MRBV entry. a. iOvCa147-F8 and iOvCa147-G4 cells were seeded at 75,000 cells per well of a 24-
well plate. After 24 h, cells were infected with MRBV at an MOI of 1 for 1 h. Supernatant was collected and non-cell associated virus was titrated
using Vero cells; supernatant from infections containing no cells were used as a control for total uninfected virus. b. Western blot were performed
using lysates collected from iOvCa147-F8 and iOvCa147-G4 cells infected with MRBV at an MOI of 1, or UV-inactivated MRBV and no virus as controls.
Actin served as a loading control. The graph represents quantification of LDLR expression performed using Bio-Rad Image Lab software and normalized
to actin. c. Two different MRBV-sensitive subclones iOvCa147-F8 and iOvCa147-E2 cells were seeded at 20,000 cells per well of a 48-well plate.
Cells were transfected with siNT or siLDLR and 48 h post-transfection, cells were harvested for protein lysates. Western blot for LDLR was performed
and actin was used as a loading control. d. iOvCa147- F8 and iOvCa147-E2 cells transfected with siNT or siLDLR were treated with 100 nM of RAP for
1 h at 48 h post-transfection followed by MRBV infection for another 1 h. media was collected for titration of MRBV virus on Vero cells via plaque assay;
treatments containing no cells were performed for normalization. e. iOvCa147- F8 and iOvCa147-E2 cells transfected with siNT or siLDLR were treated
with 100 nM of RAP for 1 h at 48 h post-transfection followed by MRBV infection for another 1 h. Cells were assayed for viability using CellTiter-Glo at
72 h post-infection. (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001, as determined by one-way ANOVA and Tukey’s posthoc test)
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subclones, iOvCa147-G4 and -B3 was performed after
MRBV infection. Neither MRBV-sensitive nor -resistant
HGSC subclone cell lines elicited a potent IFN antiviral
signaling response after MRBV infection (Fig. 4a). The
A549 human lung adenocarcinoma cell line, which is
known to elicit a robust type I interferon response to
virus infection with rapid upregulation of the IFNB1
gene and thus serves as a positive control [13],
responded to MRBV infection with a robust increase in
IFNB1 expression.
To further determine whether other secreted factors
elicited an effect on sensitivity to MRBV, iOvCa147-F8
and -G4 cell lines were treated with conditioned media
from the reciprocal subclone cell line (i.e., media swap)
immediately prior to MRBV infection. Forty-eight
hours after infection, we observed that the conditioned
media from the reciprocal cell line did not alter sen-
sitivity or resistance to MRBV oncolytic infection
(Fig. 4b). Extracellular factors other than IFNB1 pro-
duced after an acute MRBV infection may affect HGSC
cell sensitivity or resistance; thus we performed another
conditioned media swapping experiment, but using
media shortly following MRBV infection. Again, there
were no differences in cell viability when conditioned
media from acutely-infected cells were swapped, in-
dicating that secreted resistance factors are not trans-
ferred between iOvCa147-F8 (sensitive) and -G4
(resistance) subclones (Fig. 4c).
Direct contact in MRBV-sensitive and -resistant cell co-
cultures restores oncolysis
Lastly, we sought to determine whether direct inter-
action of MRBV-sensitive and –resistant cells within a
heterogeneous tumour cell population might impact
oncolytic efficacy. We predicted that efficient MRBV
infection and oncolysis would be restored in this context
since the original iOvCa147 mixed population cell line
was quite sensitive to MRBV oncolytic infection (Fig. 1b).
To recapitulate various iterations of a heterogeneous
tumour population, we co-cultured iOvCa147-F8 and
iOvCa147-G4 cells at multiple different ratios. Indeed,
MRBV-mediated cell killing was increased at each co-
culture ratio than what would be expected for each in-
dividual subclone if targeted independently by MRBV
(Fig. 5a). In fact, the co-culture having an equal ratio of
a
b
c
Fig. 4 Extracellular factors do not impart sensitivity to MRBV. a MRBV-
sensitive iOvCa147-F8, and MRBV-resistant iOvCa147-B3 and iOvCa147-
G4 cells were seeded at 500,000 cells per well of a 6-well plate. A549
human lung adenocarcinoma cells served as a type I IFN response
positive control cell line. The following day, cells were infected
with MRBV at an MOI of 1 or UV-inactivated MRBV for 6 h. RNA was
isolated to perform qRT-PCR using human-specific IFNB1 primers
and SYBR Green detection; GAPDH served as a normalization control.
(****, p < 0.0001, as determined by one-way ANOVA and Dunnett’s
posthoc test). b Cells were seeded at 10,000 cells per well of a 96-well
plate. After 16 h, fresh media was either (i) replaced, (ii) conditioned
media was swapped, or (iii) left unchanged between iOvCa147-F8 and
iOvCa147-G4 cells. Cells were then immediately infected with MRBV at
an MOI of 0.1 for 1 h followed by media change. CellTiter-Glo® assays
were performed for cell viability 48 h post-infection. c iOvCa147-F8 and
iOvCa-G4 cells were seeded at 10,000 cells per well of a 96-well plate.
After 16 h, cells were infected with MRBV at an MOI of 0.1 for 1 h
followed by media change. At 12 h, fresh media was either (i) replaced,
or (ii) conditioned media was swapped between iOvCa147-F8 and
iOvCa-G4 cells, or (iii) left unchanged. CellTiter-Glo® assays were per-
formed for cell viability 48 h post-infection. (Letters indicate whether
there is a statistically significant difference (p < 0.05) among conditions
as determined by one-way ANOVA and Tukey’s posthoc test)
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both sensitive iOvCa147-F8 and resistant iOvCa147-G4
cells completely restored MRBV oncolytic potential.
To directly visualize MRBV infection into each subclo-
nal cell line within mixed co-cultures, we pre-labelled
cells with cell-permeable fluorescence dyes. Individual
fluorescence labeling was achieved in iOvCa147-F8 cells
using DiI and in iOvCa147-G4 cells using CMAC prior
to co-culture. Infection was then visualized using the
a
b
c d
Fig. 5 MRBV sensitivity can be conferred to resistant cells through direct cell-cell co-culture. a iOvCa147-F8 and iOvCa147-G4 cells were seeded at
specific mixtures as indicated to a total of 100,000 cells per well of a 24-well plate. No virus mock-infections at each cell mixture was used as a
control to determine relative viability as assessed at 48 h post-infection using CellTiter-Glo®. Expected viability if there was no interaction between
subclones was calculated using the data from 100% pure iOvCa147-F8 and 100% pure iOvCa147-G4 MRBV-infected cultures. (**, p < 0.01; ****,
p < 0.0001, as determined by paired Student’s t-test) b Fluorescence images of co-cultured cells iOvCa147-F8 (red, DiI-labelled) and iOvCa147-
G4 (blue, CMAC-labelled) were captured 16 h post-infection. MRBV-infected iOvCa147-F8 cells appear yellow (GFP and DiI double-positive)
whereas MRBV-infected iOvCa147-G4 cells appear teal (GFP and CMAC double-positive). c Double-positive cells were counted for each co-
culture concentration and normalized to the total number of iOvCa147-G4 cells (black bars) to determine percent infectivity (100% iOvCa147-
F8 served as a control; white bar). (***, p < 0.001, as determined by one-way ANOVA and Dunnett’s posthoc test) d Physical separation of cells
was achieved using 0.4-μm Transwell inserts. Media was identical between both upper and lower chambers and 100,000 cells in total were
seeded (25,000 cells in the upper chamber and 75,000 cells in the lower chamber). After 24 h, media was changed and cells were infected at
50,000 viral particles (MOI 0.5) of MRBV. After 48 h, viability of the cells in the lower chamber only was measured using CellTiter-Glo® and
normalized to uninfected cells. (***, p < 0.001; ****, p < 0.0001, as determined by one-way ANOVA and Tukey’s posthoc test)
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MRBV-driven expression of GFP. We observed en-
hanced MRBV infection of iOvCa147-G4 cells by the in-
creased proportion of CMAC and GFP double-positive
cells when co-cultured with infected iOvCa147-F8 cells
(DiI and GFP double positive) (Fig. 5b). Indeed, co-
cultures achieved a 9-fold increase in MRBV-infected
iOvCa147-G4 cells when compared to MRBV infection
of iOvCa147-G4 cells alone (Fig. 5c). Finally, the require-
ment of direct cell-cell contact in these co-cultures for
efficient MRBV infection was validated by physically
separating sensitive iOvCa147-F8 and resistant iOvCa147-
G4 subclone cell lines using a porous Transwell mem-
brane during active infection. As expected, this physical
separation of cell lines abrogated the re-sensitization of
iOvCa147-G4 cells to MRBV infection (Fig. 5d). Overall,
our findings support MRBV as an effective therapeutic
agent to infect and kill HGSC cells throughout a hetero-
geneous tumour, as long as there are subpopulations of
sensitive cells to perpetuate complete oncolysis.
Discussion
There continues to be a dire and unmet need for novel
therapeutic alternatives for the treatment of metastatic
EOC due to the high rate of chemo-resistance in recur-
rent disease [20]. This is due in large part to complexity
in histological subtypes of this EOC, as well as substan-
tial genomic instability in high-grade disease that can
drive tumour heterogeneity. We previously showed the
oncolytic agent MRBV to be a potent therapeutic agent
in EOC cells in cultured cells and spheroids, thus we
sought to evaluate MRBV oncolytic efficiency in the
context of tumour heterogeneity. Using independently
isolated EOC cell lines derived directly from a patient
during her relapsed disease course, we observed diffe-
rential oncolytic efficacies for MRBV. Likewise, indi-
vidual subclones generated from a MRBV-sensitive
heterogeneous cell line isolate actually consisted of a
mixture of both sensitive and resistant subpopulations.
These findings are the first to highlight the potential im-
pact that dynamic intratumoral heterogeneity can have
on therapeutic efficacy. Our data represents the first evi-
dence for both temporal and spatial heterogeneity in
using oncolytic virus therapeutics for EOC.
Inherent cancer cell pathobiology and its response to
treatment can act as strong selective pressures to change
patterns in EOC growth, spread and ultimately therapy-
resistant disease recurrence [21]. Since debulking sur-
gery and ascites alleviation are imperative to the clinical
management of metastatic EOC [1, 2], this affords a
unique opportunity to evaluate potential impact of dy-
namic changes in ovarian tumour biology on therapeutic
efficacy and resistance mechanisms. The selective pres-
sure that would act upon the ovarian tumour cells
present in each isolate of ascites results from cytotoxic
chemotherapy administration in the patient. Indeed, over
time the patient in our study developed resistance to
standard carboplatin and paclitaxel combination chemo-
therapy as indicated in Fig. 1a. Since our in vitro studies
used MRBV as a single biologic anti-tumour agent with a
vastly different mechanism of action from chemotherapy,
it is unlikely that the tumour cells would naturally evolve
resistance to MRBV without being exposed to this select-
ive pressure during the clinical course of the disease.
An obvious limitation of extended culture of cell lines is
the accumulation of novel behaviours that do not
necessarily reflect the original primary cell population. To
minimize this potential cell culture artifact in our studies,
cell lines and subclones were cultured for a restricted
period during experimentation to limit the acquisition of
additional mutations via selective pressure. In addition,
preliminary OncoPanel™ testing did not identify any novel
gene mutation acquisition among the analyzed cell lines, at
least for the subset of hotspot mutations available using
this platform (Ramos Valdes & DiMattia, unpublished
data). Most importantly, we identified that four indepen-
dent subclones retained sensitivity to MRBV-mediated
oncolysis, whereas three other subclones exhibited a pro-
found and reproducible MRBV-resistant phenotype. Acqui-
sition of specific resistance to such an agent due to random
genetic drift in cell culture without any selective pressure
would be highly unlikely to occur with such regularity. In
fact, we made the direct observation that among four dif-
ferent ascites samples collected over time from a single pa-
tient existed changing proportions of cells with differing
sensitivity to MRBV infection and cell killing. Other evi-
dence of this potential flux in clonal evolution has been
recently documented in high-grade serous ovarian cancer,
a highly-genomically unstable and aggressive histotype of
this disease [6, 22]. It should be noted that although the
pathology of the primary tumour from the patient in our
study was of mixed high-grade serous (70%) and clear cell
(30%) histologies, we had confirmed the consistent pres-
ence of a single TP53 missense mutation in every cell line.
TP53 mutations are regarded as universal in ovarian HGSC
[4]; but we saw no evidence of any mutations commonly
seen in clear cell carcinomas of the ovary [23].
Cell surface receptor expression can act as a key control
point for oncolytic virus specific targeting of cancer cells.
Previously, we demonstrated that LDLR expression is an
important factor mediating MRBV entry and efficient
oncolysis of several established EOC cell lines [10].
Herein, we confirmed that LDLR, but not its LDLR-
related receptors, is required for MRBV binding and entry
in new patient-derived heterogeneous EOC cell lines also.
However, we were unable to show that differences in
LDLR expression level among sensitive and resistant sub-
clones is sufficient to dictate MRBV infectivity. This does
not rule out the possibility that other trophic factors may
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act in concert with LDLR directly or indirectly to define
sensitivity to MRBV infection among cell subpopulations
in EOC. From a virus entry standpoint, rhabdoviruses
utilize phospholipids, gangliosides and protein receptors,
and these general mechanisms may serve as points of
entry for MRBV as well [24, 25]. Alternatively, other ex-
trinsic factors may impact oncolytic virus anti-tumour ef-
ficacy. For instance, Ilkow and colleagues reported
recently that VSV-mediated cell killing can be modulated
by both TGFβ and FGF2 cytokines by blocking type I
interferon anti-viral responses [26]. This study showed
that secreted factors from the cancer-associated micro-
environment were implicated in affecting oncolytic virus
infection. Our results were focused on the malignant cel-
lular component of these HGSC samples, and we demon-
strated that conditioned media from EOC cells either
before or after infection did not contain secreted factors
conferring sensitivity or resistance to MRBV-mediated
oncolysis. Understanding the full repertoire of both ex-
ogenous and endogenous trophic factors utilized by
MRBV is critical to better target heterogeneous tumour
cells and their associated microenvironment while minim-
izing off-target effects at other normal tissue sites.
Our results demonstrate conclusively that direct cell-
cell contact of sensitive and resistant cell populations is re-
quired for efficient total MRBV infection. As such, we
speculate that the formation of a virological synapse al-
lows direct cell-cell transmission of MRBV from sensitive
cells to infect resistant cells. This occurs when virus as-
sembly components polarize at the site of the synaptic
junction allowing for direct transfer of mature virus to an
adjacent cell rather than having large excesses of cell-free
virus [27, 28]. For example, vesicular stomatitis virus
(VSV), can spread directly between cells via these synapses
[29]. In fact, intravenously injected VSV is rarely observed
as cell-free particles in vivo and are normally rapidly
sequestered by cells either by infection or adhesion; sur-
face attachment of VSV has been shown to increase in-
fectivity by augmenting viral passage between cells [30].
Taken together, our results directly support the premise
that MRBV, which is a VSV-related rhabdovirus, is trans-
mitted via direct cell-cell contact, and specifically to faci-
litate MRBV infection from sensitive to resistant cells.
These findings imply that even in a heterogeneous ovarian
tumour only a small subpopulation of cells needs to be
efficiently infected to result in complete oncolytic infec-
tion of the tumour. Our results also support the strategy
to use cell-based carrier systems for MRBV delivery, espe-
cially to enhance infectivity of the potentially resistant
subpopulation cells in a heterogeneous tumour [31].
Conclusions
One postulation is that cancer therapy resistance can
arise from the expansion of inherently resistant
subpopulations that are already present within a hetero-
geneous tumour. Indeed, we observed that within a
mixed population of EOC cells from a single patient
sample, there can reside both MRBV-sensitive and -re-
sistant clones of cells even prior to exposure to virus.
However, our results demonstrate that efficient MRBV
infection of neighbouring sensitive clones can render re-
sistant clones susceptible to oncolytic-mediated cell
death, which may reduce the probability of future ther-
apy resistance. Future studies would be important to dir-
ectly assess whether selective forces imposed by MRBV
treatment could eventually give rise to a dominant
MRBV resistant population of cells from heterogeneous
EOC, or if alternative adaptive responses are required to
support resistance. Direct application of heterogeneous
patient-derived tumour specimens in pre-clinical oncoly-
tics research could uncover novel strategies to better ex-
ploit these anti-tumour viral agents, like MRBV, for
broader therapeutic use in treating EOC at specific time
points during disease progression and preventing devel-
opment of resistance to oncolytic therapy.
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Additional file 1: Figure S1. Highest alteration frequency of the LDLR
gene in serous ovarian cancers. a. Mutation and gene copy-number status
for LDLR across human cancers as determined using The Cancer Genome
Atlas (TCGA) provisional datasets accessed from cBioPortal as of November
12, 2015. Ovarian cancer (serous adenocarcinoma) has the highest
prevalence of LDLR gene alterations, particularly amplifications, as compared
with all other malignancies in the data set. b. Oncoprint of serous ovarian
tumours harbouring LDLR mutations, copy-number changes, and gene
expression changes (z-score > 2) from the TCGA provisional dataset. Only
tumour samples with alterations (13%; 78/599 samples) are displayed
for clarity. c. LDLR mRNA expression as compared with gene copy-number
status among all serous ovarian tumours from the TCGA provisional dataset.
(PPTX 240 kb)
Additional file 2: Figure S2. Reduced LDLR expression in spheroids
decreases MRBV-mediated oncolysis. a. Cells were seeded into standard
tissue culture plates or ultra-low attachment (ULA) plates to form spheroids
and harvested for protein lysis 24 h after seeding. Western blotting was
performed for LDLR expression and actin served as a loading control. LDLR
expression is reduced in iOvCa147-F8 spheroids to similar levels seen in
iOvCa147-G4 cells and spheroids. b. iOvCa147-F8 and -G4 cells were seeded
at 50,000 cells per well of a 24-well ULA plate and spheroids were formed
over 72 h. Spheroids were then infected with MRBV at an MOI of 0.1 for
48 h and viability was assessed using CellTiter-Glo®; MRBV-infected adherent
cells were used for comparison. (PPTX 65 kb)
Additional file 3: Figure S3. Validation of LDLR knockdown using two
independent siRNAs. a. iOvCa147-F8 cells were seeded at 20,000 cells per
well of a 48-well dish, then transfected with each siLDLR siRNA or siNT
control for 48 h. Transfected cells were harvested for protein lysis to perform
western blotting for LDLR expression. b. Cells transfected with siLDLR-1,
siLDLR-2, or siNT, were infected with MRBV at an MOI of 0.05 for 48 h
and viability was measured using CellTiter-Glo®. (PPTX 85 kb)
Additional file 4: Figure S4. LDLR protein expression in EOC patient-
derived cell lines and subclones used in this study. Western blotting for
LDLR protein expression was performed using lysates generated from
the indicated cell lines and iOvCa147 subclones. Classification of cell
line and subclone sensitivity or resistance to MRBV infection are indicated.
(PPTX 63 kb)
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